|
1
|
Cavallo F, De Giovanni C, Nanni P, Forni G
and Lollini PL: 201: The immune hallmarks of cancer. Cancer Immunol
Immunother. 60:319–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rabinovich GA, Gabrilovich D and Sotomayor
EM: Immunosuppressive strategies that are mediated by tumor cells.
Annu Rev Immunol. 25:267–296. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Petrausch U, Poehlein CH, Jensen SM,
Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T,
Maston L, et al: Cancer immunotherapy: The role regulatory T cells
play and what can be done to overcome their inhibitory effects.
Curr Mol Med. 9:673–682. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rech AJ, Mick R, Martin S, Recio A, Aqui
NA, Powell DJ Jr, Colligon TA, Trosko JA, Leinbach LI, Pletcher CH,
et al: CD25 blockade depletes and selectively reprograms regulatory
T cells in concert with immunotherapy in cancer patients. Sci
Transl Med. 4:134ra622012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
LeBien TW and Tedder TF: B lymphocytes:
How they develop and function. Blood. 112:1570–1580. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Crawford A, Macleod M, Schumacher T,
Corlett L and Gray D: Primary T cell expansion and differentiation
in vivo requires antigen presentation by B cells. J Immunol.
176:349–3506. 2006. View Article : Google Scholar
|
|
7
|
Coughlin CM, Vance BA, Grupp SA and
Vonderheide RH: RNA-transfected CD40-activated B cells induce
functional T-cell responses against viral and tumor antigen
targets: Implications for pediatric immunotherapy. Blood.
103:2046–2054. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
DiLillo DJ, Yanaba K and Tedder TF: B
cells are required for optimal CD4+ and CD8+ T cell tumor immunity:
Therapeutic B cell depletion enhances B16 melanoma growth in mice.
J Immunol. 184:4006–4016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fillatreau S, Gray D and Anderton SM: Not
always the bad guys: B cells as regulators of autoimmune pathology.
Nat Rev Immunol. 8:391–397. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bouaziz JD, Yanaba K and Tedder TF:
Regulatory B cells as inhibitors of immune responses and
inflammation. Immunol Rev. 224:201–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lindner S, Dahlke K, Sontheimer K, Hagn M,
Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R,
et al: Interleukin 21-induced granzyme B-expressing B cells
infiltrate tumors and regulate T cells. Cancer Res. 73:2468–2479.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tadmor T, Zhang Y, Cho HM, Podack ER and
Rosenblatt JD: The absence of B lymphocytes reduces the number and
function of T-regulatory cells and enhances the antitumor response
in a murine tumor model. Cancer Immunol Immunother. 60:609–619.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olkhanud PB, Damdinsuren B, Bodogai M,
Gress RE, Sen R, Wejksza K, Malchinkhuu E, Wersto RP and Biragyn A:
Tumor-evoked regulatory B cells promote breast cancer metastasis by
converting resting CD4+ T cells to T-regulatory cells. Cancer Res.
71:3505–3515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Eliav Y, Shin SU, Schreiber TH,
Podack ER, Tadmor T and Rosenblatt JD: B lymphocyte inhibition of
antitumor response depends on expansion of Treg but is independent
of B-cell IL-10 secretion. Cancer Immunol Immunother. 62:87–99.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim S, Fridlender ZG, Dunn R, Kehry MR,
Kapoor V, Blouin A, Kaiser LR and Albelda SM: B-cell depletion
using an anti-CD20 antibody augments antitumor immune responses and
immunotherapy in nonhematopoetic murine tumor models. J Immunother.
31:446–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah S, Divekar AA, Hilchey SP, Cho HM,
Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH,
et al: Increased rejection of primary tumors in mice lacking B
cells: inhibition of antitumor CTL and TH1 cytokine responses by B
cells. Int J Cancer. 117:574–586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Inoue S, Leitner WW, Golding B and Scott
D: Inhibitory effects of B cells on antitumor immunity. Cancer Res.
66:7741–7747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franco M, Bustuoabad OD, Di Gianni PD,
Goldman A, Pasqualini CD and Ruggiero R: A serum- mediated
mechanism for concomitant resistance shared by immunogenic and
non-immunogenic murine tumors. Br J Cancer. 74:178–186. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bustuoabad OD, Ruggiero RA, Di Gianni PD,
Lombardi G, Beli C, Camerano GV, Dran GI, Schere-Levy C, Costa H,
Isturiz MA, et al: Tumor transition zone: A new putative
morphological and functional hallmark of tumor aggressiveness.
Oncol Res. 15:169–182. 2005.PubMed/NCBI
|
|
20
|
Maglioco A, Machuca D, Mundiñano J,
Cabrera G, Camicia G, Bruzzo J, Camerano G, Costa H, Ruggiero RA
and Dran GI: Lymphadenectomy exacerbates tumor growth while
lymphadenectomy plus the adoptive transfer of autologous cytotoxic
cells and low-dose cyclophosphamide induces regression of an
established murine fibrosarcoma. Cancer Immunol Immunother.
60:389–399. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chiarella P, Vulcano M, Bruzzo J,
Vermeulen M, Vanzulli S, Maglioco A, Camerano GV, Palacios V,
Fernández G, Brando RF, et al: Anti-inflammatory pretreatment
enables an efficient dendritic cell-based immunotherapy against
established tumors. Cancer Immunol Immunother. 57:701–718. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maglioco A, Machuca D, Camerano G, Costa
H, Ruggiero R and Dran GI: Regulatory B cells presence in lymph
nodes draining a murine tumor. Medicina (B Aires). 74:185–188.
2014.PubMed/NCBI
|
|
23
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matzinger P: The JAM test. A simple assay
for DNA fragmentation and cell death. J Immunol Methods.
145:185–192. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zou W: Regulatory T cells, tumour immunity
and imunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Whiteside T: Inhibiting the inhibitors:
Evaluating agents targeting cancer immunosuppression. Expert Opin
Biol Ther. 10:1019–1035. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mauri C, Gray D, Mushtaq N and Londei M:
Prevention of arthritis by interleukin 10-producing B cells. J Exp
Med. 197:489–501. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Watanabe R, Ishiura N, Nakashima H, Kuwano
Y, Okochi H, Tamaki K, Sato S, Tedder TF and Fujimoto M: Regulatory
B cells (B10 cells) have a suppressive role in murine lupus: CD19
and B10 cell deficiency exacerbates systemic autoimmunity. J
Immunol. 184:4801–4809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsushita T, Yanaba K, Bouaziz JD,
Fujimoto M and Tedder TF: Regulatory B cells inhibit EAE initiation
in mice while other B cells promote disease progression. J Clin
Invest. 118:3420–3430. 2008.PubMed/NCBI
|
|
30
|
DiLillo DJ, Matsushita T and Tedder TF:
B10 cells and regulatory B cells balance immune responses during
inflammation, autoimmunity and cancer. Ann N Y Acad Sci.
1183:38–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qin Z, Richter G, Schüler T, Ibe S, Cao X
and Blankenstein T: B cells inhibit induction of T cell-dependent
tumor immunity. Nat Med. 4:627–630. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lundy S: Killer B lymphocytes: The
evidence and the potential. Inflamm Res. 58:345–357. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong X, Tumang JR, Gao W, Bai C and
Rothstein TL: PD-L2 expression extends beyond dendritic
cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and
phosphatidylcholine binding. Eur J Immunol. 37:2405–2410. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Parekh VV, Prasad DV, Banerjee PP, Joshi
BN, Kumar A and Mishra GC: B cells activated by lipopolysaccharide,
but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T
cells: Role of TGF-beta 1. J Immunol. 170:5897–5911. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moore KW, De Waal Malefyt R, Coffman RL
and O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu
Rev Immunol. 19:683–765. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zheng SG, Wang JH, Gray JD, Soucier H and
Horwitz DA: Natural and induced CD4+CD25+ cells educate CD4+CD25-
cells to develop suppressive activity: The role of IL-2, TGF-beta,
and IL-10. J Immunol. 172:5213–5221. 2004. View Article : Google Scholar : PubMed/NCBI
|
